Table 4 List of clinical trials assessing the efficacy of different p38 inhibitors in COPD
From: p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics
NCT Numbera | Status | last update | Study Results | Interventions | Dosing | Phases | Enrollment | Publication |
|---|---|---|---|---|---|---|---|---|
NCT02815488 | Terminated | March 2019 | NAb | CHF6297 | Single and repeated doses | Phase 2 | 118 | [150] |
NCT00642148 | Completed | July 27, 2009 | NA | GW856553 (Losmapimod) | 12-weeks of treatment with GW856553 7.5 mg twice daily | Phase 2 | 306 | [149] |
NCT00144859 | Completed | July 2005 | NA | SB681323 (Dilmapimod) | 7.5 mg Per Day | Phase 2 | 82 | NA |
NCT02366637 | Terminated | May 2015 | With Results | PF-03715455 (aka compound 1ab) | Orally inhaled placebo twice a day (BID) for 4 weeks | Phase 2 | 13 | NA |
NCT01541852 | Completed | February 2014 | NA | GW856553 (Losmapimod) | 7.5 mg tablet twice daily | Phase 2 | 72 | [163] |
NCT01332097 | Completed | May 2013 | NA | BCT197 (Acumapimod) | single 75 mg oral dose of BCT197 capsules | Phase 2 | 183 | [164] |
NCT01218126 | Completed | December 21, 2011 | With Results | GW856553 (Losmapimod) | three doses of losmapimod (2.5 mg, 7.5 mg and 15 mg) twice daily | Phase 2 | 604 | |
NCT02299375 | Completed | December 21, 2011 | With Results | GW856553 (Losmapimod) | 15 mg (mg) twice daily | Phase 2 | 184 | [160] |
NCT00559910 | Completed | June 30, 2016 | NA | PH-797804 | 0.5, 3, 6 or 10 mg PH-797804 once daily and treated for 6 weeks following a 2-week run-in | Phase 2 | 230 | [55] |
NCT01937338 | Completed | April 2014 | NA | AZD7624 | nebulizer solution; 20 mg/mL for inhalation | Phase 1 | 60 | [144] |
NCT02238483 | Completed | April 4, 2016 | With Results | AZD7624 | Inhaled AZD7624 solution, 11 mg/mL | Phase 2 | 213 | [144] |
NCT01475292 | Completed | April 2012 | NA | RV568 | RV568 50 and 100 ug administered via a nebulizer once daily for 14 days | Phase 2 | 30 | [146] |
NCT01703052 | Completed | May 2012 | NA | CHF6001 | a single-dose dry-powder inhaler including 20, 100, 200, 400, 800, 1,600, and 2,000 µg and 2,400, 4,000, and 4,800 µg | Phase 1 | 74 | [165] |
NCT02386761 | Completed | May 2015 | NA | CHF6001 | a single-dose dry-powder inhaler including 2,400, 4,000, and 4,800 µg | Phase 1 | 48 | [165] |
NCT00439881 | Completed | June 2012 | NA | SB-681323 | single intravenous dose | Phase 1 | 16 | [21] |